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MCM8-9 complex promotes resection of
double-strand break ends by MRE11-RAD50-NBS1
complex
Kyung Yong Lee1, Jun-Sub Im1, Etsuko Shibata1, Jonghoon Park1, Naofumi Handa2, Stephen C. Kowalczykowski2
& Anindya Dutta1
MCM8-9 complex is required for homologous recombination (HR)-mediated repair of
double-strand breaks (DSBs). Here we report that MCM8-9 is required for DNA resection by
MRN (MRE11-RAD50-NBS1) at DSBs to generate ssDNA. MCM8-9 interacts with MRN and
is required for the nuclease activity and stable association of MRN with DSBs. The ATPase
motifs of MCM8-9 are required for recruitment of MRE11 to foci of DNA damage. Homo-
zygous deletion of the MCM9 found in various cancers sensitizes a cancer cell line to
interstrand-crosslinking (ICL) agents. A cancer-derived point mutation or an SNP on MCM8
associated with premature ovarian failure (POF) diminishes the functional activity of MCM8.
Therefore, the MCM8-9 complex facilitates DNA resection by the MRN complex during HR
repair, genetic or epigenetic inactivation of MCM8 or MCM9 are seen in human cancers, and
genetic inactivation of MCM8 may be the basis of a POF syndrome.
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D
ouble-strand break (DSB) repair is essential for the
maintenance of DNA integrity1. Deregulation of
this process leads to significant genetic instability, which
can result in the development of tumours2. DSB repair systems
are largely classified into homologous recombination (HR)
and non-homologous end joining (NHEJ). In the first step
of HR repair, MRN (MRE11-RAD50-NBS1) complex and
C-terminal binding protein (CtBP)-interacting protein (CtIP)
recognize DNA breaks, resect single-stranded DNA (ssDNA)
together with BLM/Dna2 and Exo1, and thus generate a long
stretch of 30-overhanging ssDNA3–6. Following DNA resection,
RPA proteins are recruited to the ssDNA to stabilize the
structure, and mediator proteins, including Rad51, Rad52 and
BRCA2, promote the formation of Rad51 filaments7. Recent
papers show that the endonuclease activity of MRE11 in the MRN
complex distinguishes HR from NHEJ8,9.
Interstrand-crosslinking (ICL)-inducing chemotherapy agents
such as cisplatin and mitomycin C produce lesions that are
repaired by HR10,11. Hence, inactivation of HR makes cells
very sensitive to ICL adducts, and cancers defective in HR
(for example, those with BRCA1 or BRCA2 mutations) are good
targets for treatment with cisplatin or mitomycin C. HR, as an
important part of meiosis, is also very important for the
generation of germ cells.
Even though MCM8-9 proteins have initially been identified as
components of pre-replication complexes, recent findings counter
the original suggestion that MCM8-9 is essential for DNA
replication. The Xenopus MCM8 clearly shows DNA helicase
activity in vitro12, and mutants of the Drosophila MCM8
homologue, REC, have meiotic crossover defects13. However,
mice with homozygous deletions of MCM9 are viable and fertile,
albeit with some deficits in the germ cell lineage, a lineage notable
for meiosis14. Mouse and chicken cell lines with deletions ofMCM8
or MCM9 are viable, although more sensitive to cisplatin 15–17.
A single-nucleotide polymorphism (SNP; rs16991615) that leads
to an amino-acid change from glutamic acid (Glu) to lysine (Lys)
in the gene MCM8 was found in genome-wide association analysis
to be significantly correlated with age at natural menopause18.
As a whole, the evidence suggests that MCM8-9 is more important
for HR than for DNA replication, but the exact role of MCM8-9 in
HR is unclear.
Here we show that MCM8-9 is essential for DNA resection by
the MRN complex at DSBs, and is required for proper
localization of the MRN complex to the DSBs. In addition, a
cancer cell line having homozygous deletion of the MCM9 locus
exhibits inefficient HR and high sensitivity to ICL reagents.
Inactivation of the MCM8-9 complex is seen in cancers and in
a premature ovarian failure (POF). Genetic or epigenetic
inactivation of MCM8-9 is a new mechanism by which cancers
can blunt the HR repair pathway, and as in cancers with
mutations in BRCA1 or BRCA2, cancers that inactivate MCM8-9
are susceptible to chemotherapy agents that target cells with
blunted HR.
Results
MCM8-9 is required for ssDNA generation in HR repair.
Deficiency of MCM8 or MCM9 impairs the recruitment of Rad51
on chromatin after DNA damage15,17. DNA resection by the
MRN complex, CtIP, EXO1 and DNA2, produces the ssDNA that
has to be coated by RPA before subsequent Rad51 assembly19,20.
We thus measured the accumulation of RPA at DNA damage
sites in MCM8- or MCM9-depleted cells. As reported previously,
depletion of MCM8 decreases MCM9, but depletion of MCM9
does not deplete MCM8 (Fig. 1a). Even though levels of RPA70
were unchanged, there was a decrease in cisplatin-induced RPA
foci formation on MCM8 or MCM9 depletion (Fig. 1a,b).
HeLa DR13-9 cells contain a single I-SceI cut site integrated into
their genome that is repaired by HR after cleavage by the I-SceI21.
Although the expression level of I-SceI was not diminished in
MCM8- or MCM9-depleted cells (Supplementary Fig. 1), RPA
binding to the I-SceI cut site was decreased in
cells depleted of MCM8 or MCM9 compared with control
short interfering RNA (siRNA; siGL2)-transfected cells (Fig. 1c).
To eliminate the possibility of off-target effects of siRNAs,
we rescued cisplatin-induced RPA foci formation in siMCM8-
transfected cells by stably expressing siRNA-resistant Flag-tagged
MCM8 (Flag-MCM8r; Fig. 1d,e). H2AX phosphorylation on
S139, and by inference the number of DNA breaks, was not
affected by MCM8-9 depletion, suggesting that MCM8-9
specifically affected a step after DNA break formation.
To directly examine whether MCM8-9 is required for ssDNA
generation, the generation of ssDNA at DSB sites was directly
visualized by immunostaining with anti-BrdU (5-bromodeoxyur-
idine) antibody without denaturation of the double-stranded
DNA after labelling of genomic DNA with BrdU in a previous cell
cycle. Cisplatin increased the number of cells with BrdU signal,
but this was decreased by depletion of MCM8 or MCM9 (Fig. 2a).
Similarly, cisplatin treatment of mouse embryonic fibroblast
(MEF) cells from Mcm9-null (XG/XG) mice produced fewer
ssDNA-positive cells compared with wild-type (WT) MEFs
(Fig. 2b). Cell cycle profile of the MEF cells from XG/XG mice
was not changed by the 4-h cisplatin treatment, suggesting that
the decrease in ssDNA formation could not be explained by a
change in S phase progression in these cells (Supplementary
Fig. 2). Next, we utilized a new assay for quantitatively measuring
ssDNA at regions adjoining a specific DSB site induced by the
restriction enzyme AsiSI in the estrogen receptor (ER)-AsiSI
U2OS cells22. The formation of ssDNA makes BsrG1 sites in the
adjoining DNA resistant to digestion by that enzyme, thus
allowing us to measure whether the end resection complex has
digested past each of the three BsrGI site. DSB induced by
4-hydroxytamoxifen (4-OHT) treatment resulted in more ssDNA
at the BsrG1 site closer to AsiSI cut site, but at both this site and
the next, depletion of MCM8 or MCM9 decreased the generation
of ssDNA (Fig. 2c). Depletion of MRE11 also affected ssDNA
formation at these sites, validating the assay. Therefore MCM8-9
is required for ssDNA formation at DSBs before HR.
MCM8-9 is required for MRN localization to HR repair sites.
To screen for the nuclease(s) requiring MCM8-9 activity for
ssDNA formation, we first tested which nucleases were
required for RPA focus formation after cisplatin treatment. The
knockdown of MRE11, but not EXO1 and/or DNA2, suppressed
cisplatin-induced RPA foci formation to the same extent as seen
after MCM8-9 depletion (Fig. 3a,b and Supplementary Fig. 3a,b).
This result suggested that MCM8-9 might work during the initial
DNA resection alongside the MRN complex. Therefore, we
examined whether MRN and MCM8-9 physically associate with
each other. Indeed, MCM9 immunoprecipitates contained not
only MCM8 but also MRE11, NBS1 and RAD50 (Fig. 3c, left),
and conversely RAD50 immunoprecipitates contained not only
its cofactors, NBS1 and MRE11, but also MCM8-9 (Fig. 3c, right).
The co-immunoprecipitation was performed in the presence
of the DNA intercalating chemical, ethidium bromide (EtBr),
suggesting that the MCM8-9 and MRN did not interact via a
bridging DNA molecule. Furthermore, MRE11 foci generated by
cisplatin treatment co-localized with Flag-MCM8 foci (Fig. 3d).
Chromatin immunoprecipitation (ChIP) assays on HeLa DR13-9
cells showed that all of the MRN components normally
accumulated on the I-SceI cut site following the expression of
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I-SceI, but this association was impaired on depletion of MCM8
or MCM9 (Fig. 3e). In a parallel experiment, siMCM8 or
siMCM9 decreased the number of cisplatin-induced foci formed
by all MRN complex members (Fig. 3f). On the other hand, the
recruitment of CtIP to cisplatin induced foci and to I-SceI cut
sites was not affected by depletion of MCM8-9 (Supplementary
Fig. 4a,b). Therefore, in multiple experimental systems, MCM8-9
is required for the proper localization of the MRN complex to
DSB sites for DNA resection.
ATPase activity of MCM9 is essential for the function of MRN.
MCM8 and MCM9 are related in sequence to all of the
components of the MCM2-7 complex, which unwinds duplex
DNA during DNA replication23. Human MCM8 and MCM9
contain MCM domains marked by the Walker A (WA) and
Walker B (WB) motifs important for ATP binding and
hydrolysis. Therefore, we tested whether the ATPase activities
of MCM8 or MCM9 were essential for DNA resection in HR
repair. U2OS cell lines stably expressing WA or WB motif
mutants of siRNA-resistant MCM8 or MCM9 were used. On
depletion of endogenous MCM8 or MCM9 by siRNA, WT
MCM8 and MCM9 (MCM8r-WT and MCM9r-WT) restored the
RPA- and MRE11 foci on cisplatin treatment (Fig. 4a,b). The
WA- or WB motif mutants of MCM8 or MCM9 were unable to
restore these foci.
Because knockdown of MCM8 decreased both MCM8 and
MCM9, while knockdown of MCM9 decreases that protein alone,
we focused on the MCM9 mutants from here on. The recruitment
of the DNA damage response kinase ATR/ATRIP to damaged
DNA is mediated through its interaction with RPA, which is
necessary for proper checkpoint activation24–26. Consistent with a
role of MCM9 in ssDNA formation and RPA recruitment,
phospho-Chk1 was decreased in siMCM9-transfected cells,
and phospho-Chk1 was restored following expression of
MCM9r-WT, but not WA- or WB mutants of MCM9
(Supplementary Fig. 5). The WA- or WB mutants of MCM9
may even have a dominant-negative effect on checkpoint
activation, perhaps because they interact with endogenous
MCM8 and suppress any residual activity from MCM8 alone.
The sensitivity of the cells to cisplatin was increased by siMCM9,
restored by WT MCM9, but not by WA- or WB mutants of
MCM9, suggesting that the ATPase activity of MCM9 is critical
for cell survival following treatment with ICL-inducing agents
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Figure 1 | MCM8-9 is required for RPA binding to DSB sites. (a) Immunoblots of lysates from U2OS cells transfected with indicated siRNAs, 4 h after
addition of cisplatin. (b) Decrease of RPA70 foci on depletion of MCM8 or MCM9. RPA70 immunofluorescence images shown at left and cells having
over 20 foci of RPA70 were counted as positive cells on the right. Scale bar, 10mm. ***Po0.005; Student’s t-test. (c) ChIP assay in HeLa DR13-9 cells.
Fold signal of RPA70 at I-SceI cut site relative to control site 2 kb upstream of cut site in cell treated with indicated siRNAs. *Po0.05; Student’s t-test.
(d) Immunoblot of U2OS cells stably transfected with empty vector (EV) or plasmid expressing siMCM8 resistant, Flag-MCM8r, 48 h after transfection of
siRNAs. (e) Restoration of RPA foci formation by siMCM8-resistant Flag-MCM8. Quantification of RPA70 or gH2AX foci-positive cells as in Fig. 1b.
***Po0.005; Student’s t-test. All error bars represent s.d. of the mean from triplicates. DAPI, 40,60-diamidino-2-phenylindole.
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(Fig. 4c and Supplementary Fig. 6). WT MCM9 partly restored
HR efficiency to HeLa DR13-9 cells depleted of endogenous
MCM9, whereas WA- or WB mutants of MCM9 did not
(Fig. 4d).
Next, we examined whether the ATPase activity of MCM9 is
necessary for MRE11 recruitment to DSBs. In ChIP experiments
in HeLa DR13-9 cells, MRE11 recruitment to I-SceI cut sites was
not rescued by MCM9 with mutations in WA or B motifs (Fig. 4e).
The co-immunoprecipitation of MRE11 with MCM9 was also
inhibited by the same mutations (Fig. 4f). Furthermore, in vitro
nuclease assay on linearized pUC19 plasmid using purified HA-
MCM9 from HeLa DR13-9 cells suggested that only MCM9 WT
was associated with a strong nuclease activity (Fig. 4g).
MRE11 endonuclease initiates resection at DSBs before HR8.
We purified the MRN complex from U2OS cells stably
expressing FLAG-NBS1 and tested its endonuclease activity on
circular ØX174 ssDNA (Fig. 5a and Supplementary Fig. 7a).
MCM8 knockdown decreased the endonuclease activity of
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Figure 3 | MCM8-9 are required for the localization of MRN complex on HR repair sites. (a,b) MCM8-9 and MRE11 required for forming RPA
foci in cisplatin-treated cells. The western blot (a) and quantification of RPA70 foci-positive cells (b) after knockdown of indicated proteins in U2OS
cells. ***Po0.005; Student’s t-test. (c) MRN complex coimmunoprecipitates with MCM8-9. Endogenous MCM9 (left) or Rad50 (right) was
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localization of Flag-MCM8 and MRE11 in nuclear foci after exposure to cisplatin. Cells were pre-extracted for immunostaining. Scale bar, 10mm. (e) Defect
of MRN recruitment to I-SceI cut site in MCM8- or MCM9-depleted cells. ChIP assays were performed using indicated antibodies in HeLa DR13-9 cells 18 h
after transfecting plasmid expressing I-SceI. Fold signal at cut site relative to site 2 kb upstream as described in Fig. 1c. ***Po0.005, **Po0.01,
*Po0.05; Student’s t-test. (f) Decrease of MRN foci-positive cells in MCM8- or MCM9-depleted cells. Representative images (left) and % of MRN
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the immunoprecipitated MRN proteins, suggesting that human
MCM8-9 is required for optimal nuclease activity of the
MRN complex. Note that the nuclease activity of purified
MRN complex was inhibited by MRE11 inhibitor, mirin
(Supplementary Fig 7b). Thus, the nuclease activity in the
MRN immunoprecipitate was mainly due to MRE11, although
we cannot rule out the presence of other contaminating
endonucleases.
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Next, we purified recombinant Xenopus MCM8-MCM9 WT
(WT/WT) from baculovirus-infected insect cells to investigate
whether MCM8-9 can stimulate MRE11 endonuclease in vitro
(Fig. 5b). MCM8 WT MCM9 WA mutant (WT/WA) complexes
were to be used as inactive controls. We were thwarted
from doing the experiment by a nuclease that was associated
with the purified WT/WT MCM8-9 but not with the inactive
WT/WA MCM8-9 (Fig. 5c). Since the WA mutation of human
MCM9 decreased its association with human MRE11 (Fig. 4f),
we wondered whether insect MRE11 was co-purifying with the
Xl-WT/WT MCM8-9 complex. Remarkably, a 65-kDa protein,
corresponding in size to Drosophila MRE11 and recognized by
anti-MRE11 antibody, was associated with WT/WT but not WT/
WA MCM8-9 complex (Fig. 5d, the B lanes). Anti-MRE11
antibody immunodepleted the 65-kDa protein (Fig. 5d, the A and
I lanes) and decreased the nuclease activity associated with
MCM8-9 (Fig. 5e). Several controls showed that the WA
mutation of MCM9 did not decrease MCM8-9 complex
formation (Supplementary Fig. 8), but decreased the ATPase
activity of MCM8-9 (Supplementary Fig. 9), and that the MRE11
antibody decreased the nuclease associated with the recombinant
Xl-MCM8-9 without decreasing the amount of MCM8-9 proteins
(Supplementary Fig. 10).
These results suggest that ATPase activity of MCM8-9 complex
is required for ssDNA generation at DSBs as well as optimal
nuclease activity of the MRN. Also, ATP binding and hydrolysis
by the MCM9 in the MCM8-9 complex is essential for maximal
association with Mre11 and for the recruitment of MRN to DNA
damage sites.
Functional inactivation of MCM9 in cancers. Human cancers
frequently show homo- and heterozygous deletions or transloca-
tions on 6q22.31, the genomic region containing the MCM9
gene27–29. Copy-number variation studies in cancer genomes
collated at CBioPortal30, and show that 6–7% of prostate cancers
and salivary adenoid cystic carcinomas, and a smaller fraction of
other cancers have homozygous deletion of MCM9 (examples
listed in Table 1). Several cancer cell lines, including a non-small
cell lung cancer cell line, NCI-H2291, also have a homozygous
deletion of the MCM9 locus. To test whether the cancer-specific
loss ofMCM9 affected HR repair, we compared the ability of NCI-
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H2291 and NCI-H1299, a control non-small cell lung cancer cell
line, to cope with cisplatin-induced DNA damage. Although
protein levels of MCM8 and other HR repair factors were similar,
MCM9 protein was not detected in NCI-H2291 (Fig. 6a). The
NCI-H2291 cells showed fewer cells positive for RPA and MRE11
foci following cisplatin treatment (Fig. 6b). Furthermore, NCI-
2291 showed significant defect on HR efficiency compared with
NCI-1299 in an HR assay based on transient transfection of the
HR reporter and I-SceI expressing plasmids (Fig. 6c).
Complementation with hemagglutinin (HA)-tagged WT MCM9
(HA-MCM9-WT; Fig. 6d) rescued RPA foci formation (nuclei
with HA-MCM9 in Supplementary Fig. 11). Clonogenic assays
showed that the deletion of MCM9 in NCI-H2291 cells also made
them more sensitive to cisplatin than those complemented with
HA-MCM9-WT (Fig. 6e). Thus, deletion of MCM9 produces a
functional defect of HR repair in this cancer cell line. In addition,
we found that several prostate cancer cell lines do not have
deletions in MCM9, but express lower levels of the MCM9 protein
compared with HEK293T cells (Fig. 6f). The cisplatin resistance of
these prostate cancer cell lines was remarkably correlated to the
amount of MCM9 protein expressed (Fig. 6g and Supplementary
Fig. 12). Therefore, epigenetic suppression of MCM9 could also
predispose cancer cells to cisplatin sensitivity.
Functional inactivation of MCM8 by mutation in cancer or POF.
Finally, we turned to a lung squamous cell carcinoma in
CBioPortal, with a point mutation that changed proline 456 in
the WA motif of MCM8 to alanine (Fig. 7a, the upper panel).
Functional studies in a cell line stably expressing siRNA-resistant
MCM8 P456A showed that this mutation inactivated MCM8
because there was a decrease of cisplatin-induced RPA70- and
MRE11 foci on knockdown of endogenous MCM8 (Fig. 7a, lower
panel). Thus, genetic and epigenetic inactivation of MCM8-9 is
seen in diverse human cancers, and such inactivation is associated
with sensitivity to therapy by ICL agents.
Genome-wide association studies (GWAS) identified an SNP
on MCM8 leading to an amino-acid change (E341K) that is
associated with an early age of natural menopause18 (a POF
syndrome). MCM8 E341K was not able to rescue the RPA70- and
MRE11 foci formation seen after depletion of endogenous MCM8
(Fig. 7b,c) nor could it fully restore the sensitivity of the MCM8-
depleted cells to cisplatin (Fig. 7d). Consistent with a previous
result31, the naturally occurring SNP of MCM8 associated with
POF impairs the function of MCM8 in HR repair. Since HR
repair is an essential function of meiosis, mutational inactivation
of MCM8 may explain the genetic basis of this POF syndrome.
Discussion
DNA end resection is more pronounced in HR than in classical
NHEJ1. In this study, we show that MCM8-9 is required for
ssDNA generation at DSBs using the following three independent
approaches: (a) detection of RPA70, (b) exposure of
BrdU-labelled DNA and (c) quantitative PCR (qPCR)-based
assay to measure ssDNA adjoining a DSB (Figs 1 and 2). Several
DNA nucleases have been implicated in the resection: MRN
complex and CtIP for the initial resection/EXO1 and DNA2 for
the longer stretches of ssDNA3,32–36. It has also been suggested
that MRE11 endonuclease initiates resection followed by
bidirectional exonuclease activity of MRE11 and EXO1 to
generate ssDNA for HR8. In our hands, EXO1 and DNA2
appear dispensable for RPA focus formation after cisplatin
treatment, in contrast to the requirement of MRE11 (Fig. 3b and
Supplementary Fig. 3b), perhaps because the secondary and
extensive DNA resection attributed to EXO1 and DNA2 is slower
than that caused by MRE11, and is not necessary for forming
RPA foci. This does not mean that EXO1 and DNA2 are totally
dispensable for resection in vivo. However, the parallel effects of
MCM8-9 and MRE11 depletion on RPA focus formation is
consistent with our suggestion that MCM8-9 is particularly
involved in the initial resection by MRE11.
MCM8-9 recruits or promotes the stable association of MRN
to the DSB (Fig. 3), without much effect on CtIP recruitment.
This suggests that CtIP can be recruited to DSBs independent of
MRN, which is in line with a previous report37. Also, since the
MRN complex directly binds to DNA ends in vitro38, these results
suggest either that MCM8-9 is required in cells on top of the
direct DNA binding to recruit MRN, or that MCM8-9 prevents
the detachment of active MRN after it has been recruited.
MCM8-9 has highly conserved ATPase motifs and shows a
helicase activity in vitro12,39. We show that mutation of its
ATPase motif causes loss of interaction with MRN complex,
increase of cellular sensitivity to cisplatin as well as decrease of
HR efficiency (Figs 4 and 5). If anything, the mutant forms of
MCM9 appear to have a dominant-negative effect on checkpoint
activation (an indirect measure of ssDNA formation), HR and cell
survival after cisplatin treatment (Supplementary Fig. 5 and
Fig. 4c,d). The WA- or WB mutants of MCM9 most likely
associate with endogenous MCM8 or other endogenous proteins
to inactivate them further than seen after simple depletion of
MCM9.
MCM8-9 ATPase could be a new therapeutic target whose
inhibition would impair HR and augment the efficacy of
ICL-inducing agents during chemotherapy. However, it
remains to be elucidated how ATPase activity of MCM8-9
promotes the functional activity of MRN. Considering that
DNA helicases utilize ATP hydrolysis as an energy source40,
MCM8-9 may function as a helicase in its support of
MRN. Alternatively, the physical association of MCM9 with
MRE11 is impaired by the mutations in the WA or B motifs of
MCM9 (Fig. 4f), suggesting that ATP binding or hydrolysis is
important for the protein–protein interaction between these two
complexes.
Table 1 | A list of some of the cancers reported to have
homozygous deletion of MCM9 locus from copy-number
variation (CNV) experiments collated in CBioPortal.
Cancers with homozygous deletion of MCM9 locus
Cancers Case ID
Breast invasive carcinoma TCGA-AR-A0TW
TCGA-AR-A1AU
Glioblastoma TCGA-06-5415
TCGA-26-1442
TCGA-02-0058
Kidney renal clear cell carcinoma TCGA-CZ-5460
Ovarian serous cystadenocarcinoma TCGA-24-2267
TCGA-36-2543
Prostate adenocarcinoma PCA0119
PCA01555
PCA0126
Bladder urothelial carcinoma TCGA-H4-A2HQ
TCGA-HQ-A20E
Head and neck squamous cell carcinoma TCGA-CQ-5329
Prostate adenocarcinoma TCGA-CH-5748
TCGA-EJ-5494
TCGA-EJ-5505
TCGA-EJ-5509
TCGA-G9-6369
Skin cutaneous melanoma TCGA-D9-A149
TCGA-EE-A2MK
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Although MCM8-9 has been shown to associate weakly with
RAD51 (ref. 17), the results we present here argue against that
being the primary function of MCM8-9 in the loading of RAD51.
Instead, MCM8-9 is clearly involved in preparing the ssDNA
substrate that eventually loads RAD51.
Impaired HR makes cancers more sensitive to ICL-inducing
agents. We show that a naturally occurring homozygous deletion
of the MCM9 sensitizes a cancer cell line to ICL reagents and
leads to the HR defect (Fig. 6). The expression level of the MCM9
protein is correlated to the cisplatin resistance of some prostate
cancer cell lines (Fig. 6f,g) and a cancer-derived mutation of
MCM8 inactivated MCM8 (Fig. 7a). Thus, the deletion, point
mutation or reduced expression of MCM8 or MCM9 in cancers
that we report here should be tested in patients as a biomarker for
predicting a cancer’s sensitivity to ICL-inducing agents such as
cisplatin or mitomycin C. As a promoter of HR, MCM8 or
MCM9 may serve as a bona fide tumour suppressor similar to
other genes important for HR, BRCA1 and BRCA2. A cancer-
derived point mutation and a naturally occurring SNP on MCM8
associated with POF diminish the functional activity of MCM8
(Fig. 7). Together, with a very recent study that appeared while
this paper was under review31, our results explain how the SNP in
MCM8 impairs HR, an essential function in the germ line, and
thus could lead to a genetically determined POF syndrome.
Methods
Cell lines and siRNAs. U2OS, ER-AsiSI U2OS, HeLa DR13-9 and HEK293T cells
were grown in Dulbecco’s modified Eagle’s medium (Thermo Scientific) with 10%
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fetal bovine serum (FBS; Sigma-Aldrich) and penicillin/streptomycin (1%, Gibco).
LNCaP, PC-3 and NCI-H1299 cells were grown in RPMI 1640 (Gibco) supple-
mented with 10% FBS and 1% penicillin/streptomycin, and DU145 cells were
maintained in Minimum Essential Media (MEM) (Gibco) supplemented with 10%
FBS and 1% penicillin/streptomycin. WPE1-NB26 cells were maintained in kera-
tinocyte growth medium (Invitrogen). NCI-H2291 cells were maintained with
RPMI 1640 supplemented with 1.5 g l 1 sodium bicarbonate, 4.5 g l 1 glucose,
10mM HEPES, 1mM sodium pyruvate, 10% FBS and 1% penicillin/streptomycin.
MCM9-null MEF cells were grown in Dulbecco’s modified Eagle’s medium with
1mM sodium pyruvate, 10% FBS and 1% penicillin/streptomycin. ER-AsiSI U2OS
and HeLa DR13-9 were gifts from Tanya T. Paull and J. Parvin, respectively, and
the rest were purchased from American Type Cell Culture (Manassas, VA).
The sequences of the siRNAs used in this paper are as follows: siMCM8, 50-AG
AAGACGCUGAGGAUAUA-30; siMCM9, 50-GAUGACUUAGUGGAUAGU
U-30 ; siMRE11, 50-ACAGGAGAAGAGAUCAACU-30; siDNA2, 50-AGACAAG
GUUCCAGCGCCA-30 ; siEXO1, 50-CAAGCCUAUUCUCGUAUUU-30 .
Lipofectamine RNAi MAX (Invitrogen) was used for transfection of siRNA
following the manufacturer’s instruction. Cells were incubated overnight with
siRNAs þ Lipofectamine and harvested after 48 h in fresh medium.
Establishment of stable cell lines. The siRNA-resistant WT or mutant of MCM8
and MCM9 was inserted into retrovirus vector pBabe-puro and pLHCX (Clon-
tech), respectively. Retroviral vectors, together with retroviral packaging vector,
were transfected into 293T cells using Lipofectamin 2000 (Invitrogen) according to
the manufacturer’s instruction. At 48 h after transfection, viral culture supernatants
were harvested and filtered through a 0.45-mm filter, and added to the U2OS or
HeLa DR13-9 cells in the presence of 8 mgml 1 polybrene
(Sigma-Aldrich). After 48 h of infection, drug selection was carried out with
either 100mgml 1 hygromycin B (Sigma-Aldrich) or 2 mgml 1 puromycin
(Sigma-Aldrich) to select retrovirus-infected cells over a 10-day period.
Immunoblotting and antibodies. For immunoprecipitation, cells were washed
with PBS once and lysed by lysis buffer (20mM Tris-HCl (pH 7.5), 100mM NaCl,
1% Nonidet P-40 (NP-40), 5% glycerol, 1mM EDTA, 1mM MgCl2, 1mM ATP,
1mM dithiothreitol (DTT), 10mM NaF, 1mM Na3VO4 and protease inhibitors).
After sonication and centrifugation at 21,130g for 30min, 3mg of lysates was
incubated with indicated antibodies and pulled down with protein G-conjugated
agarose beads (GE Healthcare) in the presence of EtBr (10 mgml 1). For
immunoblotting, 50–70 mg of protein was subjected to SDS–polyacrylamide gel
electrophoresis analysis. Antibodies for this study were as follows: MCM8 and
MCM9 antibodies were raised in rabbits against the N- and C-terminal 100 amino
acids of MCM8 and MCM9 proteins, respectively. Anti-MCM8 (Immunoblot (IB),
1:100) and anti-MCM9 (IB, 1:500; Immunoprecipitation (IP), 12 ml per reaction)17;
anti-RPA70 (IB, 1:1,000; Immunofluorescence (IF), 1:100; NA13; Calbiochem);
anti-FLAG (IF, 1:500; F1804; Sigma); anti-a-tubulin (IB, 1:1,000; sc-5286); anti-HA
(IB, 1:1,000; IF, 1:200; sc-805) and anti-CHK1 (IB, 1:500; sc-8408) (Santa Cruz
Biotechnology); anti-RAD50 (IB, 1:1,000; IF, 1:200; IP, 10 mg per reaction;
GTX70228; Genetex); anti-EXO1 (IB, 1:1,000; ab95012) and anti-DNA2 (IB,
1:1,000; ab96488; Abcam); anti-p-CHK1 (Ser317) (IB, 1:1,000; 2344S) and anti-g-
H2AX (S139) (IB, 1:1,000; 2577L; Cell Signaling Technology); anti-MRE11 (IB,
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1:8,000; IF, 1:200; NB100-142); anti-NBS1 (IB, 1:8,000; IF, 1:200; NB100-143); and
anti-CtIP (IB, 1:1,000; IF, 1:500; NB100-79810; Novus biological). a-Tubulin was
used as loading control in most immunoblots. Uncropped images of immunoblots
presented in the main paper are provided in Supplementary Fig. 13.
Immunostaining. Cells were fixed with 4% paraformaldehyde with 0.1% Triton
X-100 in PBS for 10min and permeabilized with 0.5% Triton X-100 in PBS for 3min
at room temperature. Coverslips were incubated in 10% FBS in PBST (0.1% Triton
X-100 in PBS) overnight at 4 C, and then incubated with primary antibody for 2 h.
Cells were washed three times with PBST and incubated with either Alexa Fluor 555
anti-rabbit (1:1,000, A21429; Life Technologies) or Alexa Fluor 488 anti-mouse
(1:500, A11029; Life Technologies) immunoglobulin G secondary antibody. Cells
were mounted with a solution containing 40 ,60-diamidino-2-phenylindole (Vector
Laboratories, Inc.) before being examined under a microscope. To detect ssDNA,
U2OS cells were pre-labelled with 10mM BrdU for 24 h before the first transfection
of siRNA, and BrdU was maintained until 48 h harvest after transfection. MEFs cells
were incubated with 10mM BrdU for 48 h. In most experiments, 40mM cisplatin was
added for 4 h before harvest and pre-extraction was performed using 0.5% Triton
X-100 in PBS for 1min only for BrdU staining (1:100, 555627; BD Pharmingen). A
Zeiss Axio observer A-1 equipped with an EC Plan-Apochromat ( 63/1.4 oil) and
Axio-vision software were used to obtain and analyse images, respectively. Cells
having 420 foci per cell were counted. Brightness and contrast of obtained images
were adjusted using Photoshop 7.0 (Adobe).
ChIP assay. HeLa DR13-9 cells stably expressing MCM9 (WT or mutant in WA/
WB motifs) were fixed with 1% formaldehyde for 10min at room temperature and
incubated with 0.125M glycine for 5min. Cells were lysed by lysis buffer (50mM
Tris-HCl (pH 8.0), 10mM EDTA (pH 8.0), 0.1% SDS and protease inhibitor
cocktail (Roche)) on ice for 10min followed by sonication (30 s-on/30 s-off, eight
times at 11% amplitude using Sonic Dismembrator model 500 (Fisher Scientific)).
Lysates were diluted to one-tenth using dilution buffer (50mM Tris-HCl (pH 8.0),
150mM NaCl, 1% Triton X-100, 0.1% SDS and protease inhibitor cocktail) and
incubated with protein G-conjugate dynabeads (Invitrogen), which were bound
with the indicated antibody (anti-RPA70 (5 ml), anti-RAD50 (3 ml), anti-MRE11
(2ml), anti-NBS1 (2ml) or anti-CtIP (2ml) was mixed with 20ml dynabeads for each
reaction). After sequential washing was done by RIPA-150 (50mM Tris-HCl
(pH 8.0), 150mM NaCl, 1mM EDTA, 1% Triton X-100, 0.1% SDS and 0.1%
sodium deoxycholate), RIPA-500 (same components with RIPA-150 except for
500mM NaCl), LiCl buffer (10mM Tris-HCl (pH 8.0), 0.15M LiCl, 1mM EDTA,
0.5% NP-40 and 0.5% sodium deoxycholate) and Tris-EDTA (TE) buffer, the
pellets were incubated in elution buffer (10mM Tris-HCl (pH 8.0), 300mM NaCl
and 5mM EDTA) and 0.5% SDS at 65 C for 8 h. The eluted DNA was recovered
by phenol:chloroform extraction and analysed by qPCR using ABI 7300 real-time
PCR system (Applied Biosystems). Primers sequences used for qPCR were as
follows: I-SceI cut site (F1, 50-TACGGCAAGCTGACCCTGAA-30 ; R1, 50-GAAG
TCGTGCTGCTTCATGT-30) and 2 kb upstream of cut site (control) (F2, 50-GCC
CATATATGGAGTTCCGC-30 ; R2, 50-CCCTATTGGCGTTACTATGG-30)
Quantitative resection assay using the ER-AsiSI system. A quantitative
resection assay22 to quantitatively measure ssDNA intermediates was performed.
ER-AsiSI U2OS cells were mixed with 37 C 0.6% low-melting temperature agarose
(FMC Bioproducts) in PBS at a concentration of 6 106 cells per ml. Fifty
microlitres of cell suspension was solidified as an agar ball by dropping on a
Parafilm (Bemis). The agar ball was serially treated by 1ml of EDTA-sarcosine-
proteinase (ESP) buffer (0.5M EDTA, 2% N-lauroylsarcosine, 1mgml 1
proteinase K and 1mM CaCl2 (pH 8.0)) and high salt (HS) buffer (1.85M NaCl,
0.15 M KCl, 5mM MgCl2, 2mM EDTA, 4mM Tris and 0.5% Triton X-100
(pH 7.5)) for 20 h per each time at 16 C with rotation, followed by washing with 1
ml of phosphate buffer (8mM Na2HPO4, 1.5mM KH2PO4, 133mM KCl and
0.8mM MgCl2 (pH 7.4)) for 6 1 h at 4 C with rotation. After heating of the agar
ball at 70 C for 10min, it was diluted 15-fold with 70 C ddH2O and mixed with
2 NEB restriction enzyme buffer 4. Sixty microlitres of genomic DNA sample
was digested or mock-digested with 60 units of restriction enzyme, BsrGI (New
England Biolabs) at 37 C overnight. Three microlitres of mock- or BsrGI-digested
samples was used as templates in 20 ml of qPCR reaction containing 0.5 mM of each
primer and ABsolute Blue qPCR SYBR Green ROX (Thermo Scientific) using ABI
7300 real-time PCR system (Applied Biosystems).
HR assay. HeLa DR13-9 cells having stable expression of siRNA-resistant MCM9
were used for HR assay17,21. siMCM9 was transfected for 24 h, followed by
transfection with the I-SceI expression vector pCbASce41 using Lipofectamine2000
(Invitrogen) for 48 h. For HR assay of NCI-H1299 and NCI-H2291 cells, each 2 mg
of the DSB recombination reporter pDR-GFP-hprt42 and pCbASce was mixed and
co-transfected into those cell lines using Lipofectamine2000 for 48 h. In the mean
time, 2 mg of the modified enhanced green fluorescent protein (EGFP) expression
vector (NZ-EGFP)43 was separately transfected into those cells to evaluate the
transfection efficiency. The green fluorescent protein (GFP)-expressing cells were
counted in flow cytometric analysis (BD FACSCalibur). The HR efficiency was
calculated by normalizing the GFP% to the transfection efficiency in each cell lines.
Purification of Xenopus MCM8-9 from Sf9 cells. Sf9 cells (1 106 cells per ml,
2 l), grown in suspension culture in Grace’s medium supplemented with 10% FBS
at 27 C, were infected with baculoviruses expressing combinations of His-tagged
Xenopus MCM8 with WT or WA mutant of His-tagged MCM9. After 2 days at
27 C, cells were harvested by centrifugation at 1,200g for 15min at 4 C, and
washed once with PBS. The pellets were resuspended in 50ml of lysis buffer
(20mM Tris-HCl (pH7.4), 100mM NaCl, 0.1% NP-40, 10mM MgCl2, 5mM
2-mercaptoethanol, 10mM NaF, 2mM Na2VO3, 10% glycerol and protease
inhibitor). The cells were kept on ice for 10min and then lysed by sonication
(10 s-on/10 s-off, two times at 20% amplitude using Sonic Dismembrator model
500 (Fisher Scientific)). The lysates were collected by centrifugation at 13,000 r.p.m.
for 30min at 4 C. The cleared lysate was mixed with Ni-NTA agarose beads
(Qiagen) for 1 h and the beads were washed with lysis buffer supplemented with
20mM imidazole. Bound proteins were eluted with lysis buffer supplemented with
200mM imidazole, and then diluted fivefold with dilution buffer (20mM Tris-HCl
(pH 7.4), 0.1% NP-40, 10mM MgCl2, 5mM 2-mercaptoethanol and 10% glycerol).
The eluted proteins were applied to Hitrap Heparin HP column (Amersham
Pharmacia Biotech) in the fast protein liquid chromatography (FPLC), and 1-ml
fractions were collected in elution buffer with a linear gradient from 50mM to 1M
NaCl. The peak fractions were pooled and desalted by a PD-10 desalting column
(GE Healthcare Life Sciences). These were next applied to a Hitrap Q HP column
(Amersham Pharmacia Biotech) in the FPLC, and 1-ml fractions were collected in
elution buffer with a linear gradient from 100mM to 500mM NaCl. Final peak
fractions were concentrated by using Amicon Ultra Centrifugal filters (Millipore),
and elution buffer was changed into storage buffer (20mM Tris-HCl (pH 7.4),
100mM NaCl, 0.01% Triton X-100, 10% glycerol and 1mM DTT) by a PD-10
desalting column. To check the purity in each step of purifications, small aliquots
of each fraction was run on a 8% SDS–PAGE gel and silver-stained using a Silver
Stain Kit (Pierce).
Immunodepletion of insect MRE11 from purified MCM8-9. The protein
G-conjugated agarose beads conjugated with anti-MRE11 antibody were incubated
with purified proteins at 4 C overnight and separated from supernatant. One-fifth
of the input protein before immunodepletion (B) or after immunodepletion (A)
and the total immunoprecipitate (I) were loaded on 8% SDS–PAGE gel and
detected by anti-human MRE11 antibody in the western blot technique.
In vitro nuclease assay. To purify FLAG-tagged NBS1 or MCM9 protein, we
used U2OS and HeLa DR13-9 cell lines that stably express FLAG-NBS1 and
HA-MCM9, respectively. Cells were transfected with siGL2, siMCM8 or siMCM9
for 48 h and each of the lysates were obtained by the same procedures as used for
immunoprecipitation assays. Ten microlitres of anti-FLAG M2 affinity gel (A2220,
Sigma) or EZview Red Anti-HA Affinity beads (E6779, Sigma) was incubated with
1.5 or 3mg of lysate overnight at 4 C, and washed with lysis buffer four times and
then with elution buffer (62.5mM HEPES (pH 7.4), 62.5mM KCl, 5% glycerol,
1mM DTT and 50mgml 1 BSA) accompanied by rotation for 5min each wash.
Finally, proteins were eluted by incubation with 20 ml of elution buffer
supplemented with 150 mgml 1 FLAG or HA peptide (sigma). The in vitro
nuclease assay was done as previously published with slight modifications8,36.
pUC19 (1.88 or 3.75 nM) plasmid linearized by HindIII was mixed with the
indicated amount of purified MCM8-9 or purified MRN (FLAG-NBS1) in reaction
buffer (20mM HEPES (pH 7.5), 0.1mM DTT, 5mM MnCl2, 2mM ATP,
0.1mgml 1 BSA and 0.05% Triton X-100) for 15 or 30min at 37 C. Alternatively,
100 ng of circular ØX174 ssDNA virion DNA (New England Biolabs) was mixed
with purified MRN (FLAG-NBS1) in reaction buffer (30mM Tris-HCl (pH 7.5),
1mM DTT, 25mM KCl, 200 ng acetylated BSA, 0.4% DMSO and 5mM MnCl2) in
the presence of 8mM ATP for indicated times (Fig. 5a) at 37 C. The reaction was
stopped by adding 0.2mgml 1 proteinase K, 50mM EDTA and 3% SDS (final
concentrations) by incubating for 20min, and then the reaction products were
loaded on 1% native agarose gel. DNA was stained with EtBr, visualized by
FluorChem Q (Proteinsimple) and quantified by ImageJ software.
ATPase assay. The indicated amount of purified MCM8-9 was incubated with
reaction buffer containing 25mM HEPES-NaOH (pH 7.5), 50mM sodium acetate,
5mM magnesium acetate, 1mM DTT, 0.1mgml 1 BSA and 1.5 nmol of
[g-32P]ATP (6,000 Ci mmol 1, Perkin-Elmer) at 60 C for 1 h. Two microlitres of
each sample (15ml) was spotted onto a thin-layer chromatography (TLC) plate
(Sigma-Aldrich) followed by development in 1 M formic acid and 0.5M LiCl, and
ATP hydrolysis was visualized by autoradiography using X-ray film (Kodak).
Cell survival assay. U2OS cell lines, which stably expressed WT or mutants of the
WA or WB motif of MCM9, and various prostate cancer cells were used for the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The
indicated amount of cisplatin (Sigma-Aldrich) was incubated with cells for 24 h, and
cell viability was measured by MTT assay, following the manufacturer’s protocol
(Promega, CellTiter 96 Non-Radioactive Cell Proliferation Assay (MTT)). To deplete
endogenous MCM9 from stable U2OS cells, siMCM9 was transfected into cells at
24 h before cisplatin treatment. For the clonogenic assay, U2OS cell lines having WT
or mutants of MCM8 or MCM9 were transfected with the indicated siRNA and
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plated on a six-well plate after 24 h. The indicated concentration of cisplatin was
added for 5 h, beginning at 42 h after siRNA transfection. At day 5 after DNA
damage, the colonies were stained with crystal violet. NCI-H2291 cells were plated
and transfected with the indicated plasmid using Lipofectamine2000 (Invitrogen).
After transfection, 10,000 cells of each transfectant were plated into one well of a six-
well plate, and incubation with 2mM of cisplatin was started at 36 h after transfec-
tion. Cisplatin was washed out with fresh medium after 24 h. The colonies were
stained with crystal violet at 12 days after DNA damage and quantified using Gene
Tools software (Syngene).
References
1. Ciccia, A. & Elledge, S. J. The DNA damage response: making it safe to play
with knives. Mol. Cell 40, 179–204 (2010).
2. Aparicio, T., Baer, R. & Gautier, J. DNA double-strand break repair pathway
choice and cancer. DNA Repair (Amst) 19, 169–175 (2014).
3. Sartori, A. A. et al. Human CtIP promotes DNA end resection. Nature 450,
509–514 (2007).
4. Williams, R. S. et al. Nbs1 flexibly tethers Ctp1 and Mre11-Rad50 to coordinate
DNA double-strand break processing and repair. Cell 139, 87–99 (2009).
5. Mimitou, E. P. & Symington, L. S. Nucleases and helicases take center stage in
homologous recombination. Trends Biochem. Sci. 34, 264–272 (2009).
6. Imamura, O. & Campbell, J. L. The human Bloom syndrome gene suppresses
the DNA replication and repair defects of yeast DNA2 mutants. Proc. Natl
Acad. Sci. USA 100, 8193–8198 (2003).
7. San Filippo, J., Sung, P. & Klein, H. Mechanism of eukaryotic homologous
recombination. Annu. Rev. Biochem. 77, 229–257 (2008).
8. Shibata, A. et al. DNA double-strand break repair pathway choice is directed by
distinct MRE11 nuclease activities. Mol. Cell 53, 7–18 (2014).
9. Cannavo, E. & Cejka, P. Sae2 promotes dsDNA endonuclease activity within
Mre11-Rad50-Xrs2 to resect DNA breaks. Nature 514, 122–125 (2014).
10. Long, D. T., Raschle, M., Joukov, V. & Walter, J. C. Mechanism of
RAD51-dependent DNA interstrand cross-link repair. Science 333, 84–87
(2011).
11. Kim, H. & D’Andrea, A. D. Regulation of DNA cross-link repair by the Fanconi
anemia/BRCA pathway. Genes Dev. 26, 1393–1408 (2012).
12. Maiorano, D., Cuvier, O., Danis, E. & Mechali, M. MCM8 is an MCM2-7-
related protein that functions as a DNA helicase during replication elongation
and not initiation. Cell 120, 315–328 (2005).
13. Blanton, H. L. et al. REC, Drosophila MCM8, drives formation of meiotic
crossovers. PLoS Genet. 1, e40 (2005).
14. Hartford, S. A. et al. Minichromosome maintenance helicase paralog MCM9 is
dispensible for DNA replication but functions in germ-line stem cells and
tumor suppression. Proc. Natl Acad. Sci. USA 108, 17702–17707 (2011).
15. Lutzmann, M. et al. MCM8- and MCM9-deficient mice reveal gametogenesis
defects and genome instability due to impaired homologous recombination.
Mol. Cell 47, 523–534 (2012).
16. Nishimura, K. et al. Mcm8 and Mcm9 form a complex that functions in
homologous recombination repair induced by DNA interstrand crosslinks.
Mol. Cell 47, 511–522 (2012).
17. Park, J. et al. The MCM8-MCM9 complex promotes RAD51 recruitment at
DNA damage sites to facilitate homologous recombination. Mol. Cell. Biol. 33,
1632–1644 (2013).
18. He, C. et al. Genome-wide association studies identify loci associated with age
at menarche and age at natural menopause. Nat. Genet. 41, 724–728 (2009).
19. Symington, L. S. & Gautier, J. Double-strand break end resection and repair
pathway choice. Annu. Rev. Genet. 45, 247–271 (2011).
20. Stracker, T. H. & Petrini, J. H. The MRE11 complex: starting from the ends.
Nat. Rev. Mol. Cell Biol. 12, 90–103 (2011).
21. Ransburgh, D. J., Chiba, N., Ishioka, C., Toland, A. E. & Parvin, J. D.
Identification of breast tumor mutations in BRCA1 that abolish its function in
homologous DNA recombination. Cancer Res. 70, 988–995 (2010).
22. Zhou, Y., Caron, P., Legube, G. & Paull, T. T. Quantitation of DNA double-
strand break resection intermediates in human cells. Nucleic Acids Res. 42, e19
(2013).
23. Bochman, M. L. & Schwacha, A. The Mcm complex: unwinding the mechanism
of a replicative helicase. Microbiol. Mol. Biol. Rev. 73, 652–683 (2009).
24. Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of
RPA-ssDNA complexes. Science 300, 1542–1548 (2003).
25. Andreassen, P. R., D’Andrea, A. D. & Taniguchi, T. ATR couples FANCD2
monoubiquitination to the DNA-damage response. Genes Dev. 18, 1958–1963
(2004).
26. Pichierri, P. & Rosselli, F. The DNA crosslink-induced S-phase checkpoint
depends on ATR-CHK1 and ATR-NBS1-FANCD2 pathways. EMBO J. 23,
1178–1187 (2004).
27. Braggio, E. et al. Genomic analysis of marginal zone and lymphoplasmacytic
lymphomas identified common and disease-specific abnormalities. Mod.
Pathol. 25, 651–660 (2012).
28. Kim, J. H. et al. Integrative analysis of genomic aberrations associated with
prostate cancer progression. Cancer Res. 67, 8229–8239 (2007).
29. Sung, C. O. et al. Genomic profiling combined with gene expression profiling in
primary central nervous system lymphoma. Blood 117, 1291–1300 (2011).
30. Cerami, E. et al. The cBio cancer genomics portal: an open platform for
exploring multidimensional cancer genomics data. Cancer Discov. 2, 401–404
(2012).
31. AlAsiri, S. et al. Exome sequencing reveals MCM8 mutation underlies ovarian
failure and chromosomal instability. J. Clin. Invest. 125, 258–262 (2015).
32. Gravel, S., Chapman, J. R., Magill, C. & Jackson, S. P. DNA helicases Sgs1 and
BLM promote DNA double-strand break resection. Genes Dev. 22, 2767–2772
(2008).
33. Nimonkar, A. V., Ozsoy, A. Z., Genschel, J., Modrich, P. & Kowalczykowski, S.
C. Human exonuclease 1 and BLM helicase interact to resect DNA and initiate
DNA repair. Proc. Natl Acad. Sc.i USA 105, 16906–16911 (2008).
34. Liao, S., Toczylowski, T. & Yan, H. Identification of the Xenopus DNA2 protein
as a major nuclease for the 5’-43’ strand-specific processing of DNA ends.
Nucleic Acids Res. 36, 6091–6100 (2008).
35. Mimitou, E. P. & Symington, L. S. DNA end resection: many nucleases make
light work. DNA Repair (Amst) 8, 983–995 (2009).
36. Nimonkar, A. V. et al. BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN
constitute two DNA end resection machineries for human DNA break repair.
Genes Dev. 25, 350–362 (2011).
37. Chen, L., Nievera, C. J., Lee, A. Y. & Wu, X. Cell cycle-dependent complex
formation of BRCA1.CtIP.MRN is important for DNA double-strand break
repair. J. Biol. Chem. 283, 7713–7720 (2008).
38. de Jager, M. et al. Human Rad50/Mre11 is a flexible complex that can tether
DNA ends. Mol. Cell 8, 1129–1135 (2001).
39. Kanemaki, M. T. The dimeric Mcm8-9 complex of Xenopus laevis likely has a
conserved function for resistance to DNA damage. Cell Cycle 12, 1338–1339
(2013).
40. Mohaghegh, P. & Hickson, I. D. DNA helicase deficiencies associated with
cancer predisposition and premature ageing disorders. Hum. Mol. Genet. 10,
741–746 (2001).
41. Richardson, C., Moynahan, M. E. & Jasin, M. Double-strand break repair by
interchromosomal recombination: suppression of chromosomal translocations.
Genes Dev. 12, 3831–3842 (1998).
42. Pierce, A. J., Hu, P., Han, M., Ellis, N. & Jasin, M. Ku DNA end-binding protein
modulates homologous repair of double-strand breaks in mammalian cells.
Genes Dev. 15, 3237–3242 (2001).
43. Pierce, A. J., Johnson, R. D., Thompson, L. H. & Jasin, M. XRCC3 promotes
homology-directed repair of DNA damage in mammalian cells. Genes Dev. 13,
2633–2638 (1999).
Acknowledgements
We thank Drs Maria Jasin and Tanya T. Paull for supplying the plasmids for HR assay
and the ER-AsiSI U2OS cells, respectively. Also, we thank members of the Dutta
laboratory for their helpful discussions. This work was supported by R01 CA60499 and
CA166054 (to A.D.).
Author contributions
K.Y.L. and A.D. designed the study, while K.Y.L. executed most of the experiments and
wrote the first draft of the paper. J.-S.I. and J.P. initiated the ChIP experiments. E.S.
generated and purified Xenopus MCM8-9 recombinant proteins in insect cells. N.H.
observed the nuclease activity in purified Xenopus MCM8-9. S.C.K. and A.D. discussed
results and edited the paper.
Additional information
Supplementary Information accompanies this paper at http://www.nature.com/
naturecommunications
Competing financial interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
How to cite this article: Lee, K. Y. et al. MCM8-9 complex promotes resection of
double-strand break ends by MRE11-RAD50-NBS1 complex. Nat. Commun. 6:7744
doi: 10.1038/ncomms8744 (2015).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated otherwise
in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material.
To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms8744
12 NATURE COMMUNICATIONS | 6:7744 |DOI: 10.1038/ncomms8744 |www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
